Liquidia Technologies, Inc. (LQDA): Price and Financial Metrics


Liquidia Technologies, Inc. (LQDA): $4.24

-0.12 (-2.75%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LQDA POWR Grades


  • Sentiment is the dimension where LQDA ranks best; there it ranks ahead of 76.77% of US stocks.
  • LQDA's strongest trending metric is Stability; it's been moving down over the last 85 days.
  • LQDA's current lowest rank is in the Quality metric (where it is better than 8.38% of US stocks).

LQDA Stock Summary

  • LQDA's price/sales ratio is 30.11; that's higher than the P/S ratio of 94.65% of US stocks.
  • Revenue growth over the past 12 months for Liquidia Corp comes in at 1,637.81%, a number that bests 99.36% of the US stocks we're tracking.
  • In terms of volatility of its share price, LQDA is more volatile than 92.18% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Liquidia Corp are NVCN, SMTC, BLI, GBT, and QUIK.
  • LQDA's SEC filings can be seen here. And to visit Liquidia Corp's official web site, go to www.liquidia.com.

LQDA Valuation Summary

  • LQDA's price/sales ratio is 19.3; this is 407.89% higher than that of the median Healthcare stock.
  • LQDA's price/sales ratio has moved down 3.8 over the prior 38 months.
  • Over the past 38 months, LQDA's price/sales ratio has gone down 3.8.

Below are key valuation metrics over time for LQDA.

Stock Date P/S P/B P/E EV/EBIT
LQDA 2021-08-31 19.3 1.8 -3.0 -1.9
LQDA 2021-08-30 19.4 1.8 -3.0 -1.9
LQDA 2021-08-27 19.5 1.8 -3.0 -1.9
LQDA 2021-08-26 19.7 1.8 -3.0 -2.0
LQDA 2021-08-25 19.3 1.8 -3.0 -1.9
LQDA 2021-08-24 19.1 1.7 -2.9 -1.9

LQDA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • LQDA has a Quality Grade of D, ranking ahead of 6.72% of graded US stocks.
  • LQDA's asset turnover comes in at 0.106 -- ranking 153rd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows LQDA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.106 0.756 -1.103
2021-06-30 0.075 0.771 -1.558
2021-03-31 0.049 0.756 -2.131
2020-12-31 0.011 0.679 -2.776
2020-09-30 0.000 NA -3.022
2020-06-30 0.000 NA -2.692

LQDA Price Target

For more insight on analysts targets of LQDA, see our LQDA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.25 Average Broker Recommendation 1.5 (Moderate Buy)

LQDA Stock Price Chart Interactive Chart >

Price chart for LQDA

LQDA Price/Volume Stats

Current price $4.24 52-week high $7.78
Prev. close $4.36 52-week low $2.25
Day low $4.21 Volume 230,400
Day high $4.45 Avg. volume 806,423
50-day MA $4.86 Dividend yield N/A
200-day MA $5.00 Market Cap 272.82M

Liquidia Technologies, Inc. (LQDA) Company Bio


Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. The company was founded in 2004 and is based in Morrisville, North Carolina.


LQDA Latest News Stream


Event/Time News Detail
Loading, please wait...

LQDA Latest Social Stream


Loading social stream, please wait...

View Full LQDA Social Stream

Latest LQDA News From Around the Web

Below are the latest news stories about Liquidia Corp that investors may wish to consider to help them evaluate LQDA as an investment opportunity.

Liquidia Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MORRISVILLE, N.C., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022 Inducement Plan (the “Inducement Plan”). The stock option was granted as an inducement material to the grantee’s acceptance of employment with Liquidia (or one of its subsidiaries) as a component of the gra

Yahoo | February 23, 2022

When Will Liquidia Corporation (NASDAQ:LQDA) Become Profitable?

We feel now is a pretty good time to analyse Liquidia Corporation's ( NASDAQ:LQDA ) business as it appears the company...

Yahoo | February 15, 2022

Liquidia Technologies (LQDA) Receives a Buy from Needham

In a report released today, Serge Belanger from Needham maintained a Buy rating on Liquidia Technologies (LQDA – Research Report), with a price target of $12.00. The company's shares closed last Friday at $6.26. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 1.3% and a 38.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Liquidia Technologies with a $7.75 average price target. See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $5.

Catie Powers on TipRanks | January 10, 2022

Liquidia (NASDAQ:LQDA) shareholder returns have been splendid, earning 109% in 1 year

Unless you borrow money to invest, the potential losses are limited. On the other hand, if you find a high quality...

Yahoo | January 10, 2022

Analysts Offer Insights on Healthcare Companies: CareDx (CDNA), Biohaven Pharmaceutical Holding Co (BHVN) and Liquidia Technologies (LQDA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on CareDx (CDNA – Research Report), Biohaven Pharmaceutical Holding Co (BHVN – Research Report) and Liquidia Technologies (LQDA – Research Report). CareDx (CDNA) H.C. Wainwright analyst Yi Chen reiterated a Hold rating on CareDx today. The company's shares closed last Thursday at $40.19, close to its 52-week low of $39.16. According to TipRanks.

Catie Powers on TipRanks | January 7, 2022

Read More 'LQDA' Stories Here

LQDA Price Returns

1-mo -1.85%
3-mo -39.90%
6-mo -26.39%
1-year 53.62%
3-year -46.60%
5-year N/A
YTD -12.94%
2021 65.08%
2020 -30.99%
2019 -80.26%
2018 N/A
2017 N/A

Continue Researching LQDA

Want to see what other sources are saying about Liquidia Technologies Inc's financials and stock price? Try the links below:

Liquidia Technologies Inc (LQDA) Stock Price | Nasdaq
Liquidia Technologies Inc (LQDA) Stock Quote, History and News - Yahoo Finance
Liquidia Technologies Inc (LQDA) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4632 seconds.